GlassScriptPhysician profile
Paul A Eder
NPI 1366401515
$22,879.65
in general payments reported to CMS, 2019-2025
34 companies · $1,848 in 2025
The $1,848 reported for 2025 was more than what 85% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,672 · 2020: $1,990 · 2021: $3,816 · 2022: $3,417 · 2023: $3,252 · 2024: $3,885 · 2025: $1,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,018 · Consulting Fee: $1,850 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,017.86 |
| Consulting Fee | $1,850.00 |
| Education | $117.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $8,360.49 | 2019-2025 | Veklury, Sunlenca, Epclusa |
| Viiv Healthcare Company | $1,968.03 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Merck Sharp & Dohme LLC | $1,273.95 | 2019-2025 | Zerbaxa, Capvaxive, Pifeltro |
| Janssen Biotech, INC. | $1,201.05 | 2019-2023 | Symtuza |
| Janssen Products, LP | $1,182.32 | 2019-2023 | Symtuza |
| Abbvie INC. | $1,146.79 | 2021-2025 | Teflaro, Dalvance, Avycaz |
| Astrazeneca Pharmaceuticals LP | $1,100.03 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Paratek Pharmaceuticals, INC. | $976.45 | 2021-2023 | Nuzyra |
| Lilly USA, LLC | $605.34 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $593.47 | 2021-2025 | |
| Shionogi INC | $528.90 | 2022-2024 | Fetroja |
| Sanofi-Aventis U.S. LLC | $484.94 | 2019-2022 | |
| Novo Nordisk INC | $483.55 | 2019-2022 | |
| Insmed, INC. | $422.33 | 2019-2024 | Arikayce |
| Melinta Therapeutics, LLC | $347.93 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.55 | 2019-2023 | Jardiance |
| Astellas Pharma US INC | $293.41 | 2019-2025 | Cresemba |
| Allergan, INC. | $271.03 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $223.73 | 2019-2022 | |
| C. R. Bard, INC. & Subsidiaries | $163.64 | 2023 | Arista Ah Flexitip |
| Ferring Pharmaceuticals INC. | $124.60 | 2022-2024 | Rebyota |
| Janssen Pharmaceuticals, INC | $120.84 | 2021-2022 | |
| Amarin Pharma, INC. | $118.18 | 2020-2021 | |
| Glaxosmithkline, LLC. | $105.91 | 2020-2023 | Trelegy Ellipta |
| Comsort, INC | $100.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $89.99 | 2020-2021 | |
| Corcept Therapeutics | $58.97 | 2023-2024 | Korlym |
| Abbott Laboratories | $49.96 | 2022 | |
| Exact Sciences Corporation | $49.60 | 2025 | Cologuard Collection Kit |
| Biofire Diagnostics, LLC | $40.00 | 2021 | |
| Amgen INC. | $29.07 | 2024 | |
| Aimmune Therapeutics, INC. | $27.57 | 2024 | |
| Vifor Pharma, INC. | $23.02 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Eder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.